Literature DB >> 7948570

Invasive aspergillosis in patients with AIDS.

S H Khoo1, D W Denning.   

Abstract

The prolonged survival of profoundly immunocompromised patients with AIDS has contributed to the increasing recognition of aspergillus infections as an emerging problem. Nevertheless, many of these infections continue to be diagnosed only at autopsy. In this article we review details of 293 reported cases. Invasive aspergillosis occurs in advanced AIDS and most commonly affects the lungs, although brain involvement has also been frequently reported. The diagnosis is often difficult to make while the patient is alive, although examination of specimens obtained via bronchoalveolar lavage, percutaneous needle aspiration, or biopsy is often successful. Biopsy of the affected organ along with histologic examination and culture may be necessary for diagnosis. The dismal prognosis of invasive aspergillosis in patients with AIDS can be improved only with earlier diagnosis of disease and the availability of more-effective antifungal regimens.

Entities:  

Mesh:

Year:  1994        PMID: 7948570     DOI: 10.1093/clinids/19.supplement_1.s41

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

1.  Role of IL-10 in invasive aspergillosis: increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosis.

Authors:  K V Clemons; G Grunig; R A Sobel; L F Mirels; D M Rennick; D A Stevens
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 2.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

3.  Detection of Aspergillus DNA in bronchoalveolar lavage fluid of AIDS patients by the polymerase chain reaction.

Authors:  E Bart-Delabesse; A Marmorat-Khuong; J M Costa; M L Dubreuil-Lemaire; S Bretagne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

4.  Invasive pulmonary aspergillosis due to Emericella nidulans var. echinulata, successfully cured by voriconazole and micafungin.

Authors:  Jin Yu; Xiangdong Mu; Ruoyu Li
Journal:  J Clin Microbiol       Date:  2013-01-30       Impact factor: 5.948

5.  Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo.

Authors:  J Mosquera; P A Warn; J Morrissey; C B Moore; C Gil-Lamaignere; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

6.  Proton-pumping-ATPase-targeted antifungal activity of a novel conjugated styryl ketone.

Authors:  E K Manavathu; J R Dimmock; S C Vashishtha; P H Chandrasekar
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

7.  Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.

Authors:  K L Oakley; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 8.  Virulence factors of medically important fungi.

Authors:  L H Hogan; B S Klein; S M Levitz
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

9.  Efficacy of TAK-457, a novel intravenous triazole, against invasive pulmonary Aspergillosis in neutropenic mice.

Authors:  Ryogo Hayashi; Naomi Kitamoto; Yuji Iizawa; Takashi Ichikawa; Katsumi Itoh; Tomoyuki Kitazaki; Kenji Okonogi
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

10.  Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis.

Authors:  Brad E Morrison; Stacy J Park; Jill M Mooney; Borna Mehrad
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.